Novel therapies are changing treatment paradigms in metastatic prostate cancer

Eric Powers, Georgia Sofia Karachaliou, Chester Kao, Michael R. Harrison, Christopher J. Hoimes, Daniel J. George, Andrew J. Armstrong, Tian Zhang

Research output: Contribution to journalReview articlepeer-review

50 Scopus citations


Metastatic castration-resistant prostate cancer (mCRPC) remains a terminal diagnosis with an aggressive disease course despite currently approved therapeutics. The recent successful development of poly ADP-ribose polymerase (PARP) inhibitors for patients with mCRPC and mutations in DNA damage repair genes has added to the treatment armamentarium and improved personalized treatments for prostate cancer. Other promising therapeutic agents currently in clinical development include the radiotherapeutic 177-lutetium-prostate-specific membrane antigen (PSMA)-617 targeting PSMA-expressing prostate cancer and combinations of immunotherapy with currently effective treatment options for prostate cancer. Herein, we have highlighted the progress in systemic treatments for mCRPC and the promising agents currently in ongoing clinical trials.

Original languageEnglish (US)
Article number144
JournalJournal of Hematology and Oncology
Issue number1
StatePublished - Dec 1 2020
Externally publishedYes


  • Androgen receptor inhibitors (ARIs)
  • Castration-resistant prostate cancer
  • Metastatic prostate cancer
  • Polyadenosine diphosphate [ADP]-ribose polymerase (PARP) inhibitor
  • Prostate-specific membrane antigen (PSMA)

ASJC Scopus subject areas

  • Hematology
  • Molecular Biology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Novel therapies are changing treatment paradigms in metastatic prostate cancer'. Together they form a unique fingerprint.

Cite this